J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
Willis H. Navarro,Fausto R. Loberiza,Ruta Bajorunaite,Koen van Besien,Julie M. Vose,Hillard M. Lazarus,J. Douglas Rizzo +6 more
TL;DR: In light of the inability to find differences in survival among overweight, obese, and normal-weight patients, obesity alone should not be viewed as a contraindication to proceeding with auto-HCT for lymphoma when it is otherwise indicated.
Journal ArticleDOI
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: Report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes
Nicolaus Kröger,Ulrike Bacher,Peter Bader,Sebastian Böttcher,Michael J. Borowitz,Peter Dreger,Issa F. Khouri,Homer Macapintac,Eduardo Olavarria,Jerald P. Radich,Wendy Stock,Julie M. Vose,Daniel J. Weisdorf,Andre Willasch,Sergio Giralt,Michael R. Bishop,Alan S. Wayne +16 more
TL;DR: The current knowledge about the utilization of sensitive monitoring techniques based on tumor-specific markers and donor cell chimerism and how these methods might augment the standard definitions of posttransplant remission, persistence, progression, relapse, and the prediction of relapse are summarized.
Journal ArticleDOI
Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.
Alyssa Bouska,Weiwei Zhang,Qiang Gong,Javeed Iqbal,Anna Scuto,Julie M. Vose,Maja Ludvigsen,Kai Fu,D. D. Weisenburger,Timothy C. Greiner,Randy D. Gascoyne,Andreas Rosenwald,German Ott,Elias Campo,Lisa M. Rimsza,Jan Delabie,Elaine S. Jaffe,Rita M. Braziel,Jean M. Connors,C. I. Wu,C. I. Wu,Louis M. Staudt,Francesco d'Amore,Timothy W. McKeithan,W. C. Chan +24 more
TL;DR: In this paper, the exomes of 12 cases with paired FL and tFL biopsies were sequenced and identified 45 recurrently mutated genes in the FL-tFL data set and 39 in the tFL cases.
Journal ArticleDOI
Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis
Andrew M. Evens,Ranjana H. Advani,Oliver W. Press,Izidore S. Lossos,Julie M. Vose,Francisco J. Hernandez-Ilizaliturri,Barrett K. Robinson,Stavroula Otis,Liat Nadav Dagan,Ramsey Abdallah,Aimee R. Kroll-Desrosiers,Jessica L. Yarber,Jose Sandoval,Kelley V. Foyil,Linda M. Parker,Leo I. Gordon,Kristie A. Blum,Christopher R. Flowers,John P. Leonard,Thomas M. Habermann,Nancy L. Bartlett +20 more
TL;DR: Standard (non-antimetabolite) combination chemotherapy administered past the first trimester, as early as 13 weeks gestation, was associated with few complications and expected maternal survival with lymphoma occurring during pregnancy.
Journal ArticleDOI
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: Study of 39 cases
Anamarija M. Perry,David K. Crockett,Bhavana J. Dave,Pamela A. Althof,Lisa Winkler,Lynette M. Smith,Patricia Aoun,Wing C. Chan,Kai Fu,Timothy C. Greiner,Philip J. Bierman,Robert G. Bociek,Julie M. Vose,James O. Armitage,Dennis D. Weisenburger +14 more
TL;DR: The cases were genetically heterogeneous and included 11 ‘double‐hit’ lymphomas with rearrangements of both MYC and BCL2 or BCL6, and none of the immunohistochemical or genetic features was predictive of survival.